Expert Discussion: Ductal Carcinoma in situ.

Authors :: Dall P
Heil J
Banys-Paluchowski M
Krug D
Budach W
Kolberg-Liedtke C
Reimer T
Source :: Breast care (Basel, Switzerland) [Breast Care (Basel)] 2021 Dec; Vol. 16 (6), pp. 677-680. Date of Electronic Publication: 2021 Nov 11.
Publication Year :: 2021
Abstract: Competing Interests: Peter Dall: honoraria for lectures and advisory boards: Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, Seagen. Jörg Heil: no conflict of interest to declare. Maggie Banys-Paluchowski: honoraria for lectures and advisory boards: Roche, Novartis, Pfizer, Lilly, Eisai, AstraZeneca, Amgen, GSK, pfm, Daiichi Sankyo. Study support: EndoMag, Mammotome, MeritMedical. David Krug: received honoraria from Merck Sharp & Dohme, the European School of Oncology and the European Society for Medical Oncology. Wilfried Budach: no conflict of interest to declare. Cornelia Kolberg-Liedtke: no conflict of interest to declare. Toralf Reimer: no conflict of interest to declare.